SCHEMBL15564475

SCHEMBL15564475

CN(CC(c1ccccc1)n1cc(N)cn1)S(C)(=O)=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
PER2 O15055 1/20 0.36
CRY1 Q16526 1/20 0.36
CRY2 Q49AN0 1/20 0.36
USP2 O75604 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KLKB1 P03952 1/20 0.34
ITK Q08881 5/20 0.34
AURKA O14965 2/20 0.34
CCR5 P51681 1/20 0.34
GBA1 P04062 2/20 0.33
LCK P06239 1/20 0.33
CYP2C8 P10632 4/20 0.32
CYP2C9 P11712 4/20 0.32
CYP2C18 P33260 4/20 0.32
CREBBP Q92793 1/20 0.32
AOC3 Q16853 1/20 0.31
HTR2A P28223 1/20 0.31
HRH1 P35367 1/20 0.31
JAK2 O60674 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15565480 0.84 HTR2A (0.43) ALDH1A1KLKB1ITKAURKALCK
Hydrochloric Acid SCHEMBL17822228 0.83 TDP1 (0.45) ALDH1A1SMN1; SMN2KLKB1ITKAURKA
SCHEMBL15564560 0.82 ITK (0.45) ALDH1A1KLKB1ITKAURKALCK
SCHEMBL15564380 0.77 ITK (0.45) ALDH1A1KLKB1ITKCREBBPAOC3
SCHEMBL15565762 0.77 ITK (0.45) ALDH1A1KLKB1ITKCREBBPAOC3
SCHEMBL15564175 0.76 HTR2A (0.46) ALDH1A1SMN1; SMN2KLKB1ITKAURKA
SCHEMBL17822254 0.76 HTR2A (0.46) ALDH1A1SMN1; SMN2KLKB1ITKAURKA
SCHEMBL15564642 0.75 ITK (0.41) ALDH1A1KLKB1ITKAURKALCK
SCHEMBL15564620 0.74 KLKB1 (0.36) ALDH1A1KLKB1ITKCREBBPJAK2
SCHEMBL16786480 0.74 OPRM1 (0.42) ALDH1A1KLKB1ITKAURKALCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160326142-A1 PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2016-11-10 US disclosed
US-20160326142-A1 PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2016-11-10 US disclosed
US-20160326142-A1 PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2016-11-10 US disclosed
CN-104781238-A Pyrazole carboxamide compounds, compositions and methods of use HOFFMANN LA ROCHE 2015-07-15 CN disclosed
EP-2882718-A1 PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F.HOFFMANN-LA ROCHE AG (CH) 2015-06-17 EP disclosed
US-20150158851-A1 PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2015-06-11 US disclosed
US-20150158851-A1 PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2015-06-11 US disclosed
US-20150158851-A1 PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2015-06-11 US disclosed
WO-2014023258-A1 PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE F.HOFFMANN-LA ROCHE AG (CH) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158851-A1 PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE CYP3A5, GLP1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 ALDH1A1 889/4885PER2 3851/4885CRY1 2190/4885
US-20160326142-A1 PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE CYP3A5, GLP1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 ALDH1A1 889/4885PER2 3851/4885CRY1 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.